Paradigm Activates Hong Kong Trial Site as Phase 3 Nears Critical 50% Mark

Paradigm expands Phase 3 osteoarthritis trial into Asia with Hong Kong site activation

Paradigm Biopharmaceuticals (ASX: PAR) has activated its first Asian clinical trial site for the Paradigm Hong Kong Phase 3 Trial, with the Hong Kong Centre for Clinical Research now screening patients for the PARAOA012 study evaluating injectable pentosan polysulfate sodium (iPPS) in knee osteoarthritis. The site, led by Principal Investigator Dr Edith Lau Ming Chu, joins Paradigm’s existing network spanning Australia and the United States as the company targets enrolment of 466 participants globally.

The activation comes as the trial approaches a critical 50% recruitment milestone, which will trigger a planned interim analysis based on Day 112 primary endpoint data. Three additional sites in Moldova are expected to activate in the coming weeks, further expanding recruitment capacity during this pivotal enrolment phase.

The geographic expansion represents a strategic shift for the late-stage biotechnology company, positioning its data package for regulatory submissions across multiple jurisdictions whilst reducing single-region recruitment dependencies.

What is a Phase 3 clinical trial and why does geographic reach matter?

Phase 3 trials represent the final stage of testing before a company can seek regulatory approval to commercialise a therapy. These studies are designed to confirm efficacy and safety in a larger patient population than earlier-phase trials, typically involving hundreds or thousands of participants across multiple sites.

Pharmaceutical companies expand trials internationally for several reasons. Accelerated recruitment timelines reduce overall development costs and bring therapies to market faster. Diverse patient populations strengthen the evidence base for regulators, particularly when seeking approvals in multiple countries. Data collected across different regions can also support simultaneous regulatory submissions, compressing the path to commercial launch.

For Paradigm, the expansion into Asia and Eastern Europe builds a global dataset that supports the company’s stated strategy to pursue regulatory submissions beyond its home market. The addition of Hong Kong and Moldova to the existing Australian and US sites creates geographic diversification that can maintain recruitment momentum if any single region experiences slower enrolment.

Phase 3 is the highest-risk, highest-reward stage of drug development. Successful completion typically precedes commercialisation and potential revenue generation, making trial execution a key focus for investors tracking biotechnology companies.

Trial approaches critical 50% recruitment milestone

The 50% recruitment threshold represents more than a numerical midpoint. This milestone triggers the trial’s planned interim analysis, an assessment of efficacy data that can provide early signals about whether the therapy is performing as expected.

Paradigm’s Hong Kong activation is strategically timed to support the remaining enrolment phase as the trial moves past this midpoint. The company has structured its clinical operations through a dual contract research organisation (CRO) partnership: NBCD supports the Hong Kong and Moldova regions, whilst Advanced Clinical manages sites across Australia and the United States.

The PARAOA012 study employs a 1:1 randomisation design, meaning participants are equally allocated to receive either iPPS or placebo. The primary endpoint measures the change in weekly average daily pain at Day 112, whilst secondary endpoints assess physical function improvements, structural outcomes via imaging, safety data, and patient-reported outcomes.

PARAOA012 Trial Design:

• Total enrolment target: 466 participants
• Randomisation structure: 1:1 (iPPS vs placebo)
• Primary endpoint: Change in weekly average daily pain at Day 112
• Secondary endpoints: Physical function, structural imaging outcomes, safety, patient-reported measures
• Geographic sites: Australia, United States, Hong Kong, Moldova (pending activation)
• Interim analysis: Triggered after 50% recruitment milestone

The interim analysis represents a potential catalyst event for investors. Positive interim data could validate the therapy’s efficacy profile before full trial completion, though companies typically exercise caution in releasing interim results unless they meet pre-specified statistical thresholds.

Secondary endpoints extend beyond pain reduction

Whilst pain reduction serves as the primary measure, the trial’s secondary endpoints capture a broader assessment of treatment benefit. Physical function improvements reflect patients’ ability to perform daily activities, a key consideration for regulators evaluating therapies for chronic conditions like osteoarthritis. Structural outcomes assessed through imaging provide objective evidence of disease modification beyond symptomatic relief.

The trial builds on results from Paradigm’s Phase 2 PARAOA008 study, which reported pain reduction and improved joint function lasting up to 12 months in patients treated with iPPS. This durability data supports the hypothesis that the therapy may offer sustained benefit rather than requiring continuous dosing.

Multiple endpoint success would strengthen Paradigm’s regulatory submission and potential commercial positioning against existing osteoarthritis treatments, which predominantly focus on symptom management rather than disease modification.

Management site visit signals commitment to Asia expansion

Paradigm’s senior management will visit Hong Kong during the week commencing 13 April 2026 to meet with Dr Edith Lau Ming Chu and the clinical team. The visit reflects operational focus on building relationships with international investigators and ensuring quality execution as the trial network expands.

Managing Director Paul Rennie framed the timing as strategic:

Paul Rennie, Managing Director

“As we approach the important 50% recruitment milestone in the PARAOA012 study, it is timely that the Hong Kong site has come online to support the next phase of enrolment.”

The company has committed to updating the market as Moldova sites activate and patient recruitment progresses, maintaining transparency around trial execution milestones.

Hands-on management engagement with international sites suggests operational focus on trial execution quality, particularly important as the study enters a phase where recruitment pace directly impacts timeline to data readout.

What’s next for Paradigm’s Phase 3 programme

Near-term catalysts centre on Moldova site activations, progression toward the 50% recruitment milestone, and the subsequent interim analysis. Each of these events provides investors with visibility on execution against the company’s stated development timeline.

The global data strategy positions Paradigm to pursue regulatory submissions across multiple jurisdictions, potentially compressing the timeline between trial completion and commercial launch in different markets. The commercial opportunity in knee osteoarthritis remains substantial, with existing therapies predominantly offering symptomatic relief rather than disease-modifying benefits.

Clear visibility on near-term catalysts allows investors to track execution against stated objectives. The Hong Kong activation and pending Moldova sites demonstrate Paradigm’s ability to expand its global trial network whilst maintaining recruitment momentum toward the critical interim analysis milestone.

Want the Next Biotech Breakthrough in Your Inbox?

Join 20,000+ investors getting FREE breaking ASX healthcare and biotech news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at StockWire X to receive market-moving announcements the moment they break, with expert coverage already done for you.